



NOVILYTIC

THE CANARY IN THE FERMENTOR

PREVENT BATCH FAILURE WITH THE PROTEOMETER-L KIT

DRUG MANUFACTURING

A new therapeutic monoclonal antibody (mAb) takes approximately 7-10 years to bring to market¹, and the cost to develop a mAb from discovery to acceptance is over \$2 Billion².

Despite the investment, over 7% of all biopharmaceutical batches fail and roughly 1/3 of all these failures are due to batch contamination³.



NOW THERE IS AN EARLY WARNING SYSTEM TO PREVENT FAILURES RESULTING FROM QUALITY PROBLEMS

For mAb production, aggregation is a major cause for concern. The Proteometer-L Kit provides a viable solution for failures caused by aggregation. Unlike traditional post-purification analyses which could take days, our solution measures titer and aggregation problems in near real-time.

Our kit provides the world's first at-line molecular structure analysis from crude culture filtrate. Plug it into any HPLC with a fluorescence detector and it performs batch titer and relative aggregate analyses in less than 10 minutes.

Simply put, our novel early identification system helps prevent problems before they severely threaten batch purity and efficacy.

ADDITIONAL BENEFITS INCLUDE:

- NO sample preparation
- NO Protein A purification
- NO mass spectral analysis


No matter where you are in the drug-making process, this solution offers significant time and cost savings!

Email info@novilytic.com to receive your formal quotation today.

APPLICATIONS INCLUDE:

- Drug discovery
- Clone selection
- High throughput screening
- PR&D and process optimization
- Manufacturing

The kit is easy to use and we will assist with the initial setup.



¹ Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA, 323(9), 844. <https://doi.org/10.1001/jama.2020.1166>

² Congressional Budget Office. (2021). Research and development in the pharmaceutical industry. <https://www.cbo.gov/publication/57126#:~:text=The%20expected%20cost%20to%20develop,to%20more%20than%20%24%20billion.>

³ Langer, E. S. (2008, September 1). Biotech facilities average a batch failure every 40.6 weeks. BioProcess International. <https://bioprocessintl.com/analytical/downstream-validation/biotech-facilities-average-a-batch-failure-every-40-6-weeks-183158/#:~:text=The%20four%20most%20significant%20reasons,and%20failure%20to%20meet%20specifications.>